Advanced

Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.

Larsson, Anna H LU ; Johansson, Martin LU ; Wangefjord, Sakarias LU ; Gaber, Alexander LU ; Nodin, Björn LU ; Kucharzewska, Paulina LU ; Welinder, Charlotte LU ; Belting, Mattias LU ; Eberhard, Jakob LU and Johnsson, Anders LU , et al. (2011) In British Journal of Cancer 105(5). p.666-672
Abstract
Background:Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has been associated with an aggressive tumour phenotype and poor prognosis in several forms of cancer. In this study, we investigated the prognostic impact of PODXL expression in colorectal cancer (CRC).Methods:Using tissue microarrays and immunohistochemistry, PODXL expression was evaluated in 536 incident CRC cases from a prospective, population-based cohort study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to assess the impact of PODXL expression on cancer-specific survival (CSS) and overall survival (OS).Results:High PODXL expression was significantly associated with unfavourable clinicopathological... (More)
Background:Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has been associated with an aggressive tumour phenotype and poor prognosis in several forms of cancer. In this study, we investigated the prognostic impact of PODXL expression in colorectal cancer (CRC).Methods:Using tissue microarrays and immunohistochemistry, PODXL expression was evaluated in 536 incident CRC cases from a prospective, population-based cohort study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to assess the impact of PODXL expression on cancer-specific survival (CSS) and overall survival (OS).Results:High PODXL expression was significantly associated with unfavourable clinicopathological characteristics, a shorter CSS (hazard ratio (HR)=1.98; 95% confidence interval (CI) 1.38-2.84, P<0.001) and 5-year OS (HR=1.85; 95% CI 1.29-2.64, P=0.001); the latter remaining significant in multivariate analysis (HR=1.52; 95% CI 1.03-2.25, P=0.036). In addition, in curatively resected stage III (T1-4, N1-2, M0) patients (n=122) with tumours with high PODXL expression, a significant benefit from adjuvant chemotherapy was demonstrated (p(interaction) =0.004 for CSS and 0.015 for 5-year OS in multivariate analysis).Conclusion:Podocalyxin-like 1 expression is an independent factor of poor prognosis in CRC. Our results also suggest that PODXL may be a useful marker to stratify patients for adjuvant chemotherapy. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Cancer
volume
105
issue
5
pages
666 - 672
publisher
Nature Publishing Group
external identifiers
  • wos:000294207800011
  • pmid:21829192
  • scopus:80052021347
ISSN
1532-1827
DOI
10.1038/bjc.2011.295
language
English
LU publication?
yes
id
f6be382c-da3a-45fb-8e39-f76dfbe82f50 (old id 2151233)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21829192?dopt=Abstract
date added to LUP
2011-09-04 15:48:00
date last changed
2017-11-05 04:40:33
@article{f6be382c-da3a-45fb-8e39-f76dfbe82f50,
  abstract     = {Background:Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has been associated with an aggressive tumour phenotype and poor prognosis in several forms of cancer. In this study, we investigated the prognostic impact of PODXL expression in colorectal cancer (CRC).Methods:Using tissue microarrays and immunohistochemistry, PODXL expression was evaluated in 536 incident CRC cases from a prospective, population-based cohort study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to assess the impact of PODXL expression on cancer-specific survival (CSS) and overall survival (OS).Results:High PODXL expression was significantly associated with unfavourable clinicopathological characteristics, a shorter CSS (hazard ratio (HR)=1.98; 95% confidence interval (CI) 1.38-2.84, P&lt;0.001) and 5-year OS (HR=1.85; 95% CI 1.29-2.64, P=0.001); the latter remaining significant in multivariate analysis (HR=1.52; 95% CI 1.03-2.25, P=0.036). In addition, in curatively resected stage III (T1-4, N1-2, M0) patients (n=122) with tumours with high PODXL expression, a significant benefit from adjuvant chemotherapy was demonstrated (p(interaction) =0.004 for CSS and 0.015 for 5-year OS in multivariate analysis).Conclusion:Podocalyxin-like 1 expression is an independent factor of poor prognosis in CRC. Our results also suggest that PODXL may be a useful marker to stratify patients for adjuvant chemotherapy.},
  author       = {Larsson, Anna H and Johansson, Martin and Wangefjord, Sakarias and Gaber, Alexander and Nodin, Björn and Kucharzewska, Paulina and Welinder, Charlotte and Belting, Mattias and Eberhard, Jakob and Johnsson, Anders and Uhlen, M and Jirström, Karin},
  issn         = {1532-1827},
  language     = {eng},
  number       = {5},
  pages        = {666--672},
  publisher    = {Nature Publishing Group},
  series       = {British Journal of Cancer},
  title        = {Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.},
  url          = {http://dx.doi.org/10.1038/bjc.2011.295},
  volume       = {105},
  year         = {2011},
}